Gena is the Head of Business Development at Curocell, a commercial-stage cell therapy company specializing in CAR-T development and manufacturing. With previous experience from Kite Pharma as a process development scientist, Gena plays a key role in driving Curocell's global expansion and strategic partnerships by leveraging her expertise in CMC, technology transfer, and business development. Her ability to bridge scientific innovation with commercial strategy enables Curocell to advance its pipeline and establish global collaborations. In 2023, Gena led Investor Relations for foreign investors when Curocell successfully went public on the Korean stock exchange (KOSDAQ), managing communications with international investors and key stakeholders. Her leadership in IR not only strengthened investor confidence but also positioned Curocell for future growth and global market entry. With a comprehensive background spanning from early-stage research to investor relations, Gena is instrumental in expanding Curocell’s global footprint. She actively drives co-development and licensing collaborations to accelerate the development of novel CAR-T therapies and bring transformative treatments to patients worldwide.